Market Place
Sourcing Support
Applied Therapeutics Receives FDA Warning Letter
03 Dec 2024 //
FDA
Applied Therapeutics` rare disease drug gets a CRL
30 Nov 2024 //
ENDPTS
Applied Therapeutics Reports Q3 2024 Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
Applied Therapeutic to Present at UBS Global Health Conference
05 Nov 2024 //
GLOBENEWSWIRE
FDA scraps adcomm for Applied`s rare disease drug ahead of November decision
18 Sep 2024 //
FIERCE BIOTECH
Applied Therapeutics to Participate in Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Applied Therapeutics Reports Second Quarter 2024 Financial Results
07 Aug 2024 //
GLOBENEWSWIRE
Applied Therapeutics Added to Russell 3000® Index
01 Jul 2024 //
GLOBENEWSWIRE
Applied Therapeutics Reports First Quarter 2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
Applied Therapeutics At RBC Global Healthcare Conference
07 May 2024 //
GLOBENEWSWIRE
Applied Therapeutics Names New Chief Commercial Officer
15 Apr 2024 //
BIOSPACE
Applied Therapeutics Appoints Dale Hooks As CCO
15 Apr 2024 //
GLOBENEWSWIRE
Applied to Present Results from Ph 3 ARISE-HF Study at ACC 2024
04 Apr 2024 //
GLOBENEWSWIRE
Applied Provides FDA Update on PDUFA Target Action Date for Govorestat
28 Mar 2024 //
GLOBENEWSWIRE
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
06 Mar 2024 //
GLOBENEWSWIRE
Applied Therapeutics Announces Priority Review of NDA for Govorestat
28 Feb 2024 //
GLOBENEWSWIRE
Applied Therapeutics Announces $100 Million Private Placement
28 Feb 2024 //
GLOBENEWSWIRE
Applied Therapeutics Announces Positive Results from Analysis of Govorestat
15 Feb 2024 //
GLOBENEWSWIRE
Applied claims victory in phase 3 SORD fight, plots path to FDA
15 Feb 2024 //
FIERCE BIOTECH
Applied Therapeutics fails heart disease phase 3, seeks partner
06 Jan 2024 //
FIERCE BIOTECH
Applied Therapeutics Announces Results from ARISE-HF Phase 3 Study of AT-001
04 Jan 2024 //
GLOBENEWSWIRE
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat
03 Jan 2024 //
GLOBENEWSWIRE
Applied Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
02 Nov 2023 //
GLOBENEWSWIRE
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum
01 Nov 2023 //
GLOBENEWSWIRE
Applied to Present Data from Phase 3 ARISE-HF Study Evaluating AT-001
28 Sep 2023 //
GLOBENEWSWIRE
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study
28 Sep 2023 //
PRESS RELEASE
Applied Announces Plans to Submit NDA for Govorestat
06 Sep 2023 //
GLOBENEWSWIRE
Applied Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
25 Jul 2023 //
GLOBENEWSWIRE
Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD
15 Jun 2023 //
GLOBENEWSWIRE
Govorestat (AT-007) Receives Orphan Medicinal Product Designation
25 May 2023 //
GLOBENEWSWIRE
Applied Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007)
24 Apr 2023 //
GLOBENEWSWIRE
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
24 Apr 2023 //
GLOBENEWSWIRE
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
23 Mar 2023 //
GLOBENEWSWIRE
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Applied Announces Sorbitol Reduction Data From Phase 3 INSPIRE Trial
16 Feb 2023 //
GLOBENEWSWIRE
Applied Therapeutics to Present at SVB Securities Global Biopharma Conference
09 Feb 2023 //
GLOBENEWSWIRE
Applied Announces Partnership with Advanz for Commercialization of AT-007 in EU
04 Jan 2023 //
GLOBENEWSWIRE
Applied Announces Presentations at American Heart Association Scientific Session
31 Oct 2022 //
GLOBENEWSWIRE
Applied Therapeutics Announces Enrollment in Registrational PIII ARISE-HF Trial
25 Oct 2022 //
GLOBENEWSWIRE
Applied Therapeutics Announces +ve Data Trend in AT-007 ACTION-Galactosemia Kids
06 Oct 2022 //
GLOBENEWSWIRE
Applied Tx to Sponsor and Present at 2022 Galactosemia Foundation Conference
28 Jul 2022 //
GLOBENEWSWIRE
Applied Therapeutics Announces Public Offering of Common Stock and Warrants
22 Jun 2022 //
GLOBENEWSWIRE
Applied Therapeutics Announces Pricing of $30M Public Offering
22 Jun 2022 //
GLOBENEWSWIRE
EMA grants orphan medicinal product designation to Applied’s AT-007
06 Jun 2022 //
PHARMACEUTICAL-TECHNOLOGY
Applied Therapeutics Receives ODD from EMA for AT-007 for Galactosemia
03 Jun 2022 //
GLOBENEWSWIRE
Applied Therapeutics to Present at the UBS Global Healthcare Conference
19 May 2022 //
GLOBENEWSWIRE
Applied Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency
05 May 2022 //
GLOBENEWSWIRE
Applied Therapeutics to Present at the 43rd Annual Meeting of the SIMD
04 Apr 2022 //
GLOBENEWSWIRE
Applied Tx to Present at the 2022 Annual Genetics Meeting of the ACMGG
16 Mar 2022 //
GLOBENEWSWIRE
Applied Tx Reports Q4 and Year-end 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Applied Tx to Present at the Cowen and Barclays Investor Conferences
01 Mar 2022 //
GLOBENEWSWIRE
Applied Tx Supports 15th Annual Rare Disease Day
28 Feb 2022 //
GLOBENEWSWIRE
Applied Therapeutics to Present at the 11th Annual SVB Leerink Conference
10 Feb 2022 //
GLOBENEWSWIRE
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
03 Jan 2022 //
GLOBENEWSWIRE
Applied Announces Initiation of Registrational Phase 2/3 Study of AT-007
16 Dec 2021 //
GLOBENEWSWIRE
Applied Therapeutics Reports Third Quarter 2021 Financial Results
12 Nov 2021 //
GLOBENEWSWIRE
